Citryll
Business Services · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Kloosterstraat 9, Oss, North Brabant, 53...Website
www.citryll.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Citryll
Citryll is pioneering an innovative approach to immune mediated inflammatory diseases. Targeting NETs as a fundamental but previously unaddressed component of inflammation, Citryll is going beyond individual pathway management and symptom treatment to reduce inflammatory drive at the source.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Citryll your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Citryll had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Citryll
Website visits: Recent activity has been detected on your website
Check out if Citryll is spiking on competitors!
Product Launch: Get notified when Citryll launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Citryll has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Citryll has new funding data
Earning: See what the market has to say on Citryll recently announced quarterly report
Citryll, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Citryll is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Citryll is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Citryll.
Citryll financials insights
Gather financial insights about Citryll, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$17.2M
2020
Series B
$20.8M
2024
Series B
$89.9M
Citryll Tech Stack
A closer look at the technologies used by Citryll
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Funding
Funding
Citryll News & Media
FIRST PATIENT DOSED IN CITRYLL’S IMAGING STUDY EVALUATING DISTRIBUTION AND TARGET ENGAGEMENT OF CIT-013
Oss, Netherlands – 17 February 2026 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs), today announces that the first patient has been successfully dosed in its imaging study, ‘Cityview’, evaluating the distribution of radiolabeled CIT-013 in participants with rheumatoid arthritis (RA) and hidradenitis suppurativa (HS).FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIALCitryll Presents Positive Data from Phase I Study of CIT-013 in Rheumatoid Arthritis at ACR Convergence 2025
CITRYLL PRESENTS POSITIVE DATA FROM PHASE I STUDY OF CIT-013 IN RHEUMATOID ARTHRITIS AT ACR CONVERGENCE 2025Citryll doses first subject in Phase IIa trial of monoclonal antibody for RA
The study plans to recruit 88 subjects who will participate in a treatment period for six weeks.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Citryll
Sign Up For FreeTo access detailed company insights
Citryll is pioneering an innovative approach to immune mediated inflammatory diseases. Targeting NETs as a fundamental but previously unaddressed component of inflammation, Citryll is going beyond individual pathway management and symptom treatment to reduce inflammatory drive at the source.... Read More
